[{"id":"6d1ff443-edfc-4605-bcf4-493fe2fc94dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06089330","created_at":"2023-10-18T16:14:39.716Z","updated_at":"2024-07-02T16:35:32.910Z","phase":"Phase 2","brief_title":"A Study of JMT101 in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06089330","lead_sponsor":"Shanghai JMT-Bio Inc.","biomarkers":" EGFR • BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF wild-type","tags":["EGFR • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • irinotecan • becotarug (JMT101)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-18"},{"id":"2f2bb68d-0ed4-47ab-80c2-77d91b0ec73e","acronym":"BECOME","url":"https://clinicaltrials.gov/study/NCT05132777","created_at":"2021-11-24T18:55:38.743Z","updated_at":"2024-07-02T16:36:20.254Z","phase":"Phase 2","brief_title":"Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05132777 - BECOME","lead_sponsor":"Shanghai JMT-Bio Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • becotarug (JMT101)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 11/20/2021","start_date":" 11/20/2021","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2021-11-24"},{"id":"2a6b8dcb-c433-4e9d-ba0b-073084ef436d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04689100","created_at":"2021-01-19T20:48:16.536Z","updated_at":"2024-07-02T16:36:36.722Z","phase":"Phase 1","brief_title":"Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT04689100","lead_sponsor":"Shanghai JMT-Bio Inc.","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type • RAS wild-type","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • becotarug (JMT101)"],"overall_status":"Recruiting","enrollment":" Enrollment 259","initiation":"Initiation: 04/11/2017","start_date":" 04/11/2017","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2020-12-30"},{"id":"6a2891e8-e35f-4ea3-ae5a-db4942d0c5f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04448379","created_at":"2021-01-18T21:24:14.891Z","updated_at":"2024-07-02T16:36:36.822Z","phase":"Phase 1","brief_title":"Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04448379","lead_sponsor":"Shanghai JMT-Bio Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Gilotrif (afatinib) • becotarug (JMT101)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2020-12-25"}]